Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma

被引：4

作者：

Ambady, Prakash ^{[1
]}

Fu, Rongwei ^{[2
]}

Szidonya, Laszlo ^{[1
]}

Peereboom, David M. ^{[3
]}

Doolittle, Nancy D. ^{[1
]}

Neuwelt, Edward A. ^{[1
,4
,5
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA

[2] Oregon Hlth & Sci Univ, Sch Publ Hlth, Dept Clin Epidemiol & Med Informat, Portland, OR 97201 USA

[3] Cleveland Clin, Burkhardt Brain Tumor Ctr, Cleveland, OH 44106 USA

[4] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA

[5] Portland VA Med Ctr, Portland, OR 97239 USA

来源：

JOURNAL OF NEURO-ONCOLOGY | 2020年 / 147卷 / 01期

关键词：

Primary CNS lymphoma; Maintenance therapy; Rituximab; High-dose methotrexate; PRIMARY CNS LYMPHOMA; BLOOD-BRAIN-BARRIER; CHEMOTHERAPY; METHOTREXATE; DISRUPTION; SURVIVAL; THERAPY;

D O I：

10.1007/s11060-020-03411-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. Methods We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). Results Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08-0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26-1.43, P = 0.259). Conclusion We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.

引用

页码：171 / 176

页数：6

共 50 条

[1] Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma
Prakash Ambady
Rongwei Fu
Laszlo Szidonya
David M. Peereboom
Nancy D. Doolittle
Edward A. Neuwelt
[J]. Journal of Neuro-Oncology, 2020, 147 : 171 - 176
[2] MAINTENANCE THERAPY USING RITUXIMAB FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Ichikawa, Tomotsugu
Kurozumi, Kazuhiko
Date, Isao
[J]. NEURO-ONCOLOGY, 2009, 11 (06) : 970 - 970
[3] MAINTENANCE THERAPY USING RITUXIMAB FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Ichikawa, T.
Kambara, H.
Kosaka, H.
Inoue, S.
Yoshida, K.
Onishi, M.
Date, I.
[J]. NEURO-ONCOLOGY, 2008, 10 (06) : 1085 - 1085
[4] Rituximab maintenance therapy in central nervous system lymphoma?
Murawski, Niels
Pfreundschuh, Michael
[J]. LEUKEMIA & LYMPHOMA, 2009, 50 (10) : 1555 - 1556
[5] Maintenance therapy for central nervous system lymphoma with rituximab
Ney, Douglas E.
Abrey, Lauren E.
[J]. LEUKEMIA & LYMPHOMA, 2009, 50 (09) : 1548 - 1551
[6] The Role of Rituximab in Primary Central Nervous System Lymphoma
Jacoline E. C. Bromberg
Matthijs van der Meulen
Jeanette K. Doorduijn
[J]. Current Oncology Reports, 2020, 22
[7] The Role of Rituximab in Primary Central Nervous System Lymphoma
Bromberg, Jacoline E. C.
van der Meulen, Matthijs
Doorduijn, Jeanette K.
[J]. CURRENT ONCOLOGY REPORTS, 2020, 22 (08)
[8] The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
Van Dijck, Ruben
Doorduijn, Jeanette K.
Bromberg, Jacoline E. C.
[J]. CANCERS, 2021, 13 (08)
[9] Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma
Batchelor, T. T.
Lesser, G. J.
Grossman, S. A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[10] IMPACT OF ADDITIONAL RITUXIMAB TO STANDARD THERAPY ON COGNITIVE PERFORMANCES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS
van der Meulen, Matthijs
Dirven, Linda
Habets, Esther
Bakunina, Katerina
Taphoorn, Martin
van den Bent, Martin
Issa, Samar
Doorduijn, Jeanette K.
Bromberg, Jacoline E. C.
[J]. NEURO-ONCOLOGY, 2019, 21 : 159 - 159

← 1 2 3 4 5 →